SHH and pancreatic adenocarcinoma: TAP1 as the downstream target of SHH signaling enhances the drug resistance in pancreatic adenocarcinoma, providing a promising therapeutic approach for the development of more effective targeted therapies in the treatment of PDAC patients (68).